PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Genentech, Inc.

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Genentech Provides Update on Two Identical Phase III Studies of Lebrikizumab in People with Severe Asthma - Genentech, a member of the Roche Group, announced top-line results from two Phase III studies - Gene.com
Genentech Provides Update on Two Identical Phase III Studies of Lebrikizumab in People with Severe Asthma

 

NewswireToday - /newswire/ - South San Francisco, CA, United States, 2016/02/28 - Genentech, a member of the Roche Group, announced top-line results from two Phase III studies - Gene.com. SIX: RO, ROG; OTCQX: RHHB

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

• One study met its primary endpoint, showing lebrikizumab significantly reduced exacerbations in people with severe asthma; the second study did not meet this primary endpoint;
• Genentech continues to evaluate these study data to better understand the results;
• Clinical studies in asthma, COPD, atopic dermatitis and idiopathic pulmonary fibrosis are ongoing.

The LAVOLTA I-II studies were identical, double-blind, randomized, multicenter, placebo-controlled studies that evaluated the efficacy and safety of lebrikizumab in people with severe asthma.

LAVOLTA I met its primary endpoint, showing a significant reduction in the rate of asthma exacerbations in people with higher levels of serum periostin or blood eosinophils, both biomarkers of airway inflammation. In addition, this study demonstrated a significant improvement in lung function as measured by forced expiratory volume in one second (FEV1). The observed effect in the primary and secondary endpoints, however, was less than seen in the lebrikizumab Phase II trials. In contrast, the exacerbation reduction results observed in LAVOLTA II did not meet statistical significance. No new safety signals were observed in either study.

"We were hopeful these identical studies would confirm the Phase II results because there is still a significant unmet need for people with severe asthma," said Sandra Horning, M.D., chief medical officer and head of Global Product Development. "These data require further interpretation and analyses are ongoing to better understand the results and determine next steps."

Results from the studies will be submitted for presentation at upcoming medical meetings.

About LAVOLTA
LAVOLTA I and II are two identical, randomized, multicenter, placebo-controlled Phase III studies designed to evaluate the efficacy and safety of lebrikizumab in people with severe asthma that is uncontrolled despite standard-of-care treatment with an inhaled corticosteroid and a second controller medication. The studies together included more than 2,100 people across 28 countries.

The primary endpoint of both studies was the rate of asthma exacerbations over 52 weeks. The evaluation of the primary and secondary endpoints was based on a subgroup of people with higher levels of serum periostin or blood eosinophils.

About Asthma
Asthma is a chronic disease of the lungs involving inflammation and narrowing of the airways. Chronic lung inflammation is associated with airway hyper-responsiveness an exaggerated constrictive reaction in the airways of the lungs to a variety of factors including inhaled allergens and cold air and recurrent episodes of wheezing, breathlessness, chest tightness and coughing, particularly at night or in the early morning. Asthma is associated with variable airflow obstruction within the lung that is often reversible either spontaneously or with treatment.

The global prevalence of asthma is expected to reach 400 million by 2025, and a quarter of a million people worldwide are estimated to die every year from the disease. If uncontrolled, asthma places substantial limitations on daily life and is sometimes fatal. Current treatments may include daily use of an inhaled or oral corticosteroid and other controller medication such as long-acting bronchodilators.

About Lebrikizumab

Lebrikizumab is a novel humanized monoclonal antibody designed to specifically block the action of interleukin-13 (IL-13), a cytokine that is a key contributor to airway inflammation and asthma disease processes in some people. Clinical studies in asthma, chronic obstructive pulmonary disease (COPD), atopic dermatitis (AD) and idiopathic pulmonary fibrosis (IPF) are ongoing.

About Eosinophils
Eosinophils are inflammatory cells that can be present in increased numbers in the airways and blood of people with asthma (eosinophilia). Airway eosinophilia has been associated with key features of asthma. IL-13 plays an important role in attracting eosinophils from the blood to the airway, hence contributing to airway eosinophilia.

About Periostin
Periostin is a protein that has been identified as a key biomarker of inflammation in certain types of asthma. Its presence can be measured with a blood test. In people with asthma who have high levels of serum periostin, IL-13 appears to be a major contributor to their airway inflammation. An elevated serum periostin level has also been shown to be a predictor of airway eosinophilia, a prominent feature of asthma.

About Genentech in Respiratory Diseases
Genentech is committed to transforming care for patients with severe respiratory diseases. Genentech’s 25 years of respiratory experience includes approved medicines for moderate-to-severe persistent asthma, cystic fibrosis and idiopathic pulmonary fibrosis (IPF). Genentech also markets three medicines for the treatment of specific types of lung cancer. The lebrikizumab development program reflects Genentech’s personalized healthcare approach, which includes the use of periostin and eosinophils as biomarkers to identify those patients who are more likely to have more severe disease and may better respond to treatment with lebrikizumab.

About Genentech
Founded 40 years ago, Genentech (gene.com) is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious or life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Genentech, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Genentech Provides Update on Two Identical Phase III Studies of Lebrikizumab in People with Severe Asthma

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

Genentech |
Publisher Contact: Press Office - Gene.com 
650-467-6800 press[.]gene.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Genentech, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Genentech, Inc. / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

BD Announces Adoption of Windows 10 ‘Internet of Things’ for the Pyxis™ ES System
Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections
Greenphire Receives EU-US Privacy Shield Certification
The 2016 Georges Mathé Prize Recognizes Research on the Immunological Determinants of the Response to Breast Cancer Treatment
MDxHealth Announces Agreement with HIFU CLINIC Prostate Cancer Center for Distribution of SelectMDx in Poland
First Patient in Malaysia Receives TheraSphere™ Radioembolisation Therapy
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) Prefilled Syringe
BTG and Mirada Medical Announce CE Mark Certification for Simplicit90Y Dosimetry Software in Europe
FDA Grants Priority Review to Genentech’s Lucentis® (Ranibizumab Injection) Supplemental Biologics License Application
Genentech’s TECENTRIQ® (Atezolizumab) Shows Significant Survival Advantage Compared to Chemotherapy

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  JobsWare.com





 
  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)